Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID

Assenagon Asset Management S.A. lifted its position in shares of Ovid Therapeutics (NASDAQ:OVID) by 112.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 924,576 shares of the company’s stock after buying an additional 488,956 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.30% of Ovid Therapeutics worth $1,202,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Nuveen LLC bought a new stake in shares of Ovid Therapeutics in the first quarter valued at about $37,000. Jane Street Group LLC purchased a new position in Ovid Therapeutics during the 2nd quarter valued at about $47,000. Velan Capital Investment Management LP raised its holdings in shares of Ovid Therapeutics by 64.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock valued at $53,000 after purchasing an additional 63,000 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at about $53,000. Finally, Bank of America Corp DE lifted its position in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after purchasing an additional 18,841 shares during the period. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Trading Down 1.4%

NASDAQ OVID opened at $1.79 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.24 and a quick ratio of 4.24. The firm’s 50-day moving average is $1.51 and its two-hundred day moving average is $1.09. Ovid Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.01. The stock has a market capitalization of $127.11 million, a P/E ratio of -3.57 and a beta of 0.04.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.17 million. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%. On average, sell-side analysts anticipate that Ovid Therapeutics will post -0.4 earnings per share for the current year.

Trending Headlines about Ovid Therapeutics

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: LifeSci Capital initiated coverage with an “Outperform” rating and a $4.00 price target, publishing detailed quarterly and FY EPS forecasts that show improving (but still negative) losses through FY2026 — this institutional initiation and multi-quarter model give the stock a visible analyst catalyst. LifeSci Capital initiates coverage of Ovid Therapeutics (OVID) with outperform recommendation
• Positive Sentiment: HC Wainwright & Co. reiterated a buy recommendation, reinforcing sell-side support that could help sustain investor interest and trading momentum. HC Wainwright & Co. reiterates Ovid Therapeutics (OVID) buy recommendation
• Neutral Sentiment: LifeSci’s published model projects ongoing negative EPS (examples: FY2025 ~($0.46), FY2026 ~($0.38), quarterly EPS in the ~$0.08–$0.11 loss range) — the estimates provide a roadmap for expected cash burn and timing for any positive financial inflection, but they are not evidence of immediate revenue improvement.
• Neutral Sentiment: A December short-interest report shows an apparent large “increase” but lists zero shares and a 0.0 days-to-cover figure — this looks like a data glitch and shouldn’t be treated as a meaningful change in sentiment until corrected or clarified by exchanges/brokers.

Analysts Set New Price Targets

Several equities analysts recently issued reports on OVID shares. Wall Street Zen lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Lifesci Capital began coverage on shares of Ovid Therapeutics in a research note on Monday. They set an “outperform” rating and a $4.00 price objective for the company. Roth Capital began coverage on shares of Ovid Therapeutics in a report on Thursday, December 11th. They issued a “buy” rating and a $3.00 price objective on the stock. B. Riley reaffirmed a “buy” rating on shares of Ovid Therapeutics in a report on Friday, October 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ovid Therapeutics presently has a consensus rating of “Buy” and an average price target of $3.88.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.